Clinical Pearls, Innovations, and AI Updates in Diagnosing and Treating FFA and LPP

Conclusions

• Frontal fibrosing alopecia and lichen planopilaris are often underrecognized, but careful clinical inspection plus trichoscopy can improve diagnostic accuracy, especially in subtle or atypical cases.
• In men and children, LPP/FFA may present differently than the classic textbook pattern, so beard, sideburn, vertex, eyebrow, and body-hair involvement should all raise suspicion.
• Unexplained facial papules, redness, or acne-like changes can be important clues to occult FFA, and facial findings should prompt examination of the hairline.
• Because symptoms and visible inflammation do not reliably track disease activity, progression over time and standardized serial photography are more important than appearance alone.
• Biopsy remains valuable when the diagnosis is uncertain, even when trichoscopy is helpful.
• Patients with LPP/FFA may have exaggerated or misleading reactions after ablative laser procedures, so clinicians should screen for these disorders before cosmetic interventions and use caution.
• The evidence reviewed suggests that FFA may be associated more with affluence-related exposures or behaviors than with race alone, though the causal factors remain unresolved.
• Checkpoint inhibitors can trigger or worsen lichenoid scalp disease, including LPP, so medication history is important in patients with new or flaring scarring alopecia.
• Topical JAK inhibitors appear promising as well-tolerated treatments that can improve symptoms and disease activity in some patients, though more data are needed.
• Oral JAK inhibitors also show potential benefit, but responses are variable, insurance barriers are common, and stronger evidence is still needed.
• Low-dose doxycycline remains a reasonable anti-inflammatory option across lymphocytic scarring alopecias, and oral minoxidil can be useful as an adjunct to promote hair preservation or regrowth.
• AI is emerging as a useful tool for classification, severity scoring, activity assessment, progression prediction, and treatment selection in LPP/FFA, but clinicians should actively learn to incorporate it rather than ignore it.